Prelude Therapeutics IncorporatedPrelude Therapeutics IncorporatedPrelude Therapeutics Incorporated

Prelude Therapeutics Incorporated

No trades
See on Supercharts
Market capitalization
‪252.11 M‬USD
−2.18USD
‪−121.83 M‬USD
‪33.83 M‬
Beta (1Y)
3.05

About Prelude Therapeutics Incorporated

CEO
Krishna Vaddi
Headquarters
Wilmington
Employees (FY)
128
Founded
2016
ISIN
US74065P1012
FIGI
BBG00K7JY2Q6
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of PRLD is 3.72 USD — it has increased by 8.14% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Prelude Therapeutics Incorporated stocks are traded under the ticker PRLD.
Prelude Therapeutics Incorporated is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
PRLD stock is 12.17% volatile and has beta coefficient of 3.05. Check out the list of the most volatile stocks — is Prelude Therapeutics Incorporated there?
One year price forecast for Prelude Therapeutics Incorporated has a max estimate of 7.00 USD and a min estimate of 3.00 USD.
PRLD earnings for the last quarter are −0.45 USD per share, whereas the estimation was −0.58 USD resulting in a 22.86% surprise. The estimated earnings for the next quarter are −0.49 USD per share. See more details about Prelude Therapeutics Incorporated earnings.
Yes, you can track Prelude Therapeutics Incorporated financials in yearly and quarterly reports right on TradingView.
PRLD stock has fallen by 29.41% compared to the previous week, the month change is a 24.70% fall, over the last year Prelude Therapeutics Incorporated has showed a 43.21% decrease.
PRLD net income for the last quarter is ‪−33.08 M‬ USD, while the quarter before that showed ‪−30.61 M‬ USD of net income which accounts for −8.06% change. Track more Prelude Therapeutics Incorporated financial stats to get the full picture.
Today Prelude Therapeutics Incorporated has the market capitalization of ‪252.11 M‬, it has increased by 1.73% over the last week.
No, PRLD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PRLD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Prelude Therapeutics Incorporated stock right from TradingView charts — choose your broker and connect to your account.
PRLD reached its all-time high on Feb 10, 2021 with the price of 95.38 USD, and its all-time low was 1.66 USD and was reached on Nov 1, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 22, 2024, the company has 128.00 employees. See our rating of the largest employees — is Prelude Therapeutics Incorporated on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Prelude Therapeutics Incorporated technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Prelude Therapeutics Incorporated stock shows the sell signal. See more of Prelude Therapeutics Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Prelude Therapeutics Incorporated future price: according to them, PRLD price has a max estimate of 7.00 USD and a min estimate of 3.00 USD. Read a more detailed Prelude Therapeutics Incorporated forecast: see what analysts think of Prelude Therapeutics Incorporated and suggest that you do with its stocks.